Myeloma UK Impact Report 2025: For today and for tomorrow

Myeloma UK funds research and advocates for people living with myeloma across the UK. Their 2025 impact report covers multiple landmark NHS drug approvals including a world-first BVD approval, a new £1m research grant programme, the launch of a Precursor Framework for myeloma prevention, and a symptom awareness campaign reaching 1.6 million people.

Report snapshot
Multiple NHS drug approvals secured in 2025 including world-first BVD approval, benefitting thousands of myeloma patients Key Metric 1
UK's leading myeloma charity working to prevent, treat and help people live well with myeloma through research, advocacy and patient support Key Metric 2
Funding pioneering research, securing NHS treatment access, supporting patients and carers, and raising awareness of myeloma symptoms and precursor conditions Key Metric 3
16 Views

📋About

Research grants and fellowships, MyeTRIAL Partnership, Clinical Service Excellence Programme, Peer Buddy service, Myeloma Helpline (260+ languages), Knowledge is Power awareness campaign, drug appraisal advocacy, Precursor Framework

📊Key Metrics

Multiple NHS drug approvals secured in 2025 including world-first BVD approval, benefitting thousands of myeloma patients Key Metric 1
UK's leading myeloma charity working to prevent, treat and help people live well with myeloma through research, advocacy and patient support Key Metric 2
Funding pioneering research, securing NHS treatment access, supporting patients and carers, and raising awareness of myeloma symptoms and precursor conditions Key Metric 3

Key Outcomes

  • IsaVRD quadruplet treatment approved in England, Wales and Scotland — 63% of patients still in remission after five years in trials
  • Myeloma Awareness Week campaign reached over 1.6 million people with symptom awareness content
  • 86 hospitals accredited through the Clinical Service Excellence Programme since 2015; helpline now accessible in over 260 languages

📍Geography

UK-Wide

2025

Annual Report 2024/25

£20.8m raised in 2024/25 (up from £17.4m in 2023/24)
Key Metric 1
£9.6m raised from 176 legacy gifts; £14m committed to new Total Body PET-CT scanner
Key Metric 2
49,000 active supporters; 3,857 running participants (doubled in 3 years); 83p in every £1 goes directly to patients
Key Metric 3
MyChristie-MyHealth ePROMs system reduces clinician time on routine reviews by up to 23% and enables earlier symptom detection
2026

Impact Report Year Ending April 2026

2,829 children, parents, siblings and grandparents supported; 506 families with a child in treatment
Key Metric 1
220 bereaved families supported; 424 individuals on 93 boat trips; 692 individuals in 165 cabin breaks
Key Metric 2
£71,935 unlocked in essential support; 1,320 social work hours; 188 creative therapy sessions and 271 counselling sessions delivered
Key Metric 3
Families show average 0.7 point improvement across five Mo's Outcomes after support begins; biggest gains in social participation and accessing emotional support